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Abstract
Background Strength and muscle mass are predictors of relevant clinical outcomes in critically ill patients, but in hos-
pitalized patients with COVID-19, it remains to be determined. In this prospective observational study, we investigated
whether muscle strength or muscle mass are predictive of hospital length of stay (LOS) in patients with moderate to
severe COVID-19 patients.
Methods We evaluated prospectively 196 patients at hospital admission for muscle mass and strength. Ten patients
did not test positive for SARS-CoV-2 during hospitalization and were excluded from the analyses.
Results The sample comprised patients of both sexes (50% male) with a mean age (SD) of 59 (±15) years, body mass
index of 29.5 (±6.9) kg/m2. The prevalence of current smoking patients was 24.7%, and more prevalent coexisting
conditions were hypertension (67.7%), obesity (40.9%), and type 2 diabetes (36.0%). Mean (SD) LOS was 8.6 days
(7.7); 17.0% of the patients required intensive care; 3.8% used invasive mechanical ventilation; and 6.6% died during
the hospitalization period. The crude hazard ratio (HR) for LOS was greatest for handgrip strength comparing the
strongest versus other patients (1.47 [95% CI: 1.07–2.03; P = 0.019]). Evidence of an association between increased
handgrip strength and shorter hospital stay was also identified when handgrip strength was standardized according
to the sex-specific mean and standard deviation (1.23 [95% CI: 1.06–1.43; P = 0.007]). Mean LOS was shorter for
the strongest patients (7.5 ± 6.1 days) versus others (9.2 ± 8.4 days). Evidence of associations were also present for
vastus lateralis cross-sectional area. The crude HR identified shorter hospital stay for patients with greater
sex-specific standardized values (1.20 [95% CI: 1.03–1.39; P = 0.016]). Evidence was also obtained associating longer
hospital stays for patients with the lowest values for vastus lateralis cross-sectional area (0.63 [95% CI: 0.46–0.88;
P = 0.006). Mean LOS for the patients with the lowest muscle cross-sectional area was longer (10.8 ± 8.8 days) versus
others (7.7 ± 7.2 days). The magnitude of associations for handgrip strength and vastus lateralis cross-sectional area
remained consistent and statistically significant after adjusting for other covariates.
Conclusions Muscle strength and mass assessed upon hospital admission are predictors of LOS in patients with mod-
erate to severe COVID-19, which stresses the value of muscle health in prognosis of this disease.
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Introduction
Aging and chronic conditions such as type 2 diabetes increase
the risk of developing severe forms of COVID-19. Neverthe-
less, apparently healthier, younger individuals may also re-
quire hospitalization and develop poor outcomes.1–3 This
suggests that there might be undiscovered clinical features
associated with COVID-19 prognosis, with muscular parame-
ters being potential candidates.
Skeletal muscle constitutes ~40% of total body mass and
plays a pivotal role in different physiological process such as
immune response, regulation of glucose levels, protein syn-
thesis, and basal metabolic rate.4–6 Handgrip strength and
muscle mass have been shown previously to be predictive
of clinical outcomes, such as hospital length of stay (LOS)
and mortality, in distinct populations.7–11
In fact, the significance of muscle mass and strength to exer-
cise and activities of daily living has never been questioned.
Muscle also plays a central role in the response to stress in
acute conditions, a role that has been somewhat less
appreciated.12 Cases of exacerbated cytokines production (i.
e. ‘cytokine storm’) can lead to sepsis, which has been deemed
partially responsible for fatal cases of COVID-19.13 In such con-
ditions, inflammation leads to multi-organ damage, affecting
mostly pulmonary, cardiac, hepatic, vascular, and renal sys-
tems. Preservation of protein content in key tissues and or-
gans, such as the brain, heart, and liver, is essential for
survival, and it can be maintained relatively constant under
acute stressful conditions, provided muscle mass is adequate
to supply the required amino acids.14,15 Skeletal muscle is also
a major immunoregulatory organ, responsible for the produc-
tion of a wide range of soluble factors with anti-inflammatory
and immunoprotective effects, the so-called myokines, which
could help ameliorate exacerbated inflammation in this
disease.5 The potentially protective role of muscle tissue in
COVID-19 allows hypothesizing that muscle health may be an
important predictor of clinical outcomes in this disease.
Herein, we investigated whether muscle strength and mus-
cle mass assessed at hospital admission are predictive of LOS
in patients with moderate to severe COVID-19.
Methods
Study design
This is a prospective observational study conducted between
March 2020 and October 2020 in the Clinical Hospital of the
School of Medicine of the University of Sao Paulo in Brazil
(HCFMUSP) the largest quaternary referral teaching hospital
in Latin America. This study was approved by the local Ethics
Committee (Ethics Committee Approval Number
(31303720.7.0000.0068). All patients provided written in-
formed consent before entering the study. This manuscript
was reported according to the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) State-
ment and comply with ethical guidelines for publishing in
the Journal of Cachexia, Sarcopenia and Muscle.16
Participants
The inclusion criteria were (i) aged 18 or older; (ii) diagnosis
of COVID-19 by PCR for SARS-CoV-2 from nasopharyngeal
swabs or computed tomography scan findings (bilateral mul-
tifocal ground-glass opacities ≥50%) compatible with the dis-
ease; (iii) diagnosis of flu syndrome with hospitalization
criteria on hospital admission, presenting respiratory rate
≥24 breaths per minute, saturation <93% on room air or risk
factors for complications, such as heart disease, diabetes
mellitus, systemic arterial hypertension, neoplasms, immuno-
suppression, pulmonary tuberculosis, and obesity, followed
by COVID-19 confirmation. Exclusion criteria were (i) cancer
in the past 5 years; (ii) delirium; (iii) cognitive deficit that pre-
cluded the patient from reading and signing the informed
consent form; (iv) prior diagnosis of muscle degenerative dis-
ease (e.g. myopathies, amyotrophic lateral sclerosis, and
stroke); (v) patients already admitted under invasive mechan-
ical ventilation. Patients who met these criteria were consid-
ered to have moderate to severe COVID-19 according to
NIH.17 Patients or the public were not involved in the design,
or conduct, or reporting, or dissemination plans of our
research.
Data collection
All patients were evaluated in the point-of-care within <48 h
upon hospital admission for handgrip strength and vastus
lateralis cross-sectional area, by means of ultrasound imag-
ing, and were followed until medical discharge.
Handgrip strength assessments were performed with the
patient seated holding the dynamometer (TKK 5101; Takei,
Tokyo, Japan) with the dominant hand and elbow posi-
tioned at a 90° angle. Three maximum attempts of 5 s with
1 min of the interval between attempts were performed,
and the best result was used for analysis. Vastus lateralis
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Table 1 Demographics and clinical characteristics of patients at hospital admission
All patients (n = 186) Survivors (n = 174)
Sex, n (%)
Female 93 (50.0%) 88 (50.6%)
Male 93 (50.0%) 86 (49.4%)
Age, n (%)
<65 116 (62.4%) 112 (64.4%)
>65 70 (37.6%) 62 (35.6%)
Race, n (%)
White 95 (51.1%) 90 (51.7%)
Black 58 (31.2%) 52 (29.9%)
Yellow 33 (17.7%) 32 (18.4%)
Smoking status, n (%)
Never 140 (75.3%) 132 (75.9%)
Current 46 (24.7%) 42 (24.1%)
Co-morbidities, n (%)
Asthma 12 (6.5%) 11 (6.3%)
Heart failure 18 (9.7%) 16 (9.2%)
Obesity (BMI > 30) 76 (40.9%) 70 (40.2%)
Type 2 diabetes 67 (36.0%) 56 (32.2%)
COPD 7 (3.8%) 7 (4.0%)
Chronic renal disease 11 (5.9%) 9 (5.2%)
Ethilism 7 (3.8%) 6 (3.4%)
Atrial fibrillation 8 (4.3%) 8 (4.6%)
Acute myocardial infarction 13 (7.0%) 13 (7.5%)
Hypertension 126 (67.7%) 113 (64.9%)
COVID-19 testing, n (%)
Positive PCR for SARS-CoV-2 160 (86.0%) 148 (85.1%)
Positive IgG for SARS-CoV-2 26 (14.0%) 26 (14.9%)
Acute COVID-19 symptoms, n (%)
Anosmia 37 (19.9%) 35 (20.1%)
Headache 41 (22.0%) 38 (21.8%)
Runny nose 17 (9.1%) 17 (9.8%)
Diarrhoea 33 (17.7%) 31 (17.8%)
Dysgeusia 31 (17.2%) 30 (17.2%)
Dyspnoea 151 (81.2%) 141 (81.0%)
Abdominal pain 19 (10.2%) 18 (10.3%)
Chest pain 19 (10.2%) 19 (10.9%)
Fatigue 47 (25.3%) 43 (24.7%)
Fever 107 (57.5%) 99 (56.9%)
Myalgia 50 (26.9%) 47 (27.0%)
Nausea 21 (11.3%) 20 (11.5%)
Earache 8 (4.3%) 8 (4.6%)
Cough 119 (64.4%) 110 (63.2%)
Dizziness 2 (1.1.%) 2 (1.1%)
Vomiting 18 (9.7%) 18 (10.3%)
Oxygen support, n (%)
No oxygen therapy 68 (36.6) 66 (37.9)
Oxygen therapy 104 (55.9) 98 (56.3)
Non-invasive ventilation 14 (7.5) 10 (5.7)
Biochemical parameters
Haemoglobin, mean (SD), g/L 12.6 (2.9) [n = 182] 12.7 (3.0) [n = 170]
Neutrophil, mean (SD), ×103/mm3 6.6 (4.1) [n = 178] 6.5 (4.2) [n = 166]
Lymphocytes, mean (SD), ×103/mm3 1.3 (1.1) [n = 176] 1.3 (1.2) [n = 165]
Platelets, mean (SD), ×103/mm3 255.8 (126.1) [n = 181] 259.0 (128.6) [n = 169]
C-reactive protein, mean (SD), mg/L 92.3 (87.7) [n = 167] 84.5 (80.6) [n = 156]
D-dimer, mean (SD), ng/mL 2383.8 (4770.2) [n = 134] 2159.8 (3995.4) [n = 124]
Creatinine, mean (SD), mg/dL 1.4 (2.1) [n = 176] 1.2 (0.9) [n = 164]
Urea, mean (SD), mg/dL 51.8 (39.2) [n = 177] 48.6 (33.1) [n = 165]
Pulmonary commitmenta (≥50%), n (%) 42 (22.6%) 35 (18.8%)
ICU admission, n (%) 33 (17.7%) 22 (12.6)
Use of invasive mechanical ventilation, n (%) 7 (3.8) 1 (0.6%)
Hospital length of stay (day), median (IQR) 7 (4–11) 7 (4–11)
In-hospital death, n (%) 12 (6.5%) -
Handgrip strength, kgF, median (IQR) 21 (15–30) 22 (15–30)
Vastus lateralis CSA, cm3, median (IQR) 12 (12–19) 16 (12–18)
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CSA, cross-sectional area; ICU, intensive care unit; IQR, interquartile
range.
aPulmonary commitment was evaluated using chest computed tomography.
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cross-sectional area was assessed by a B-mode ultrasound
with a 7.5-MHz linear-array probe (SonoAce R3, Samsung-
Medison, Gangwon-do, South Korea) as previously
described.18 Cross-sectional area analyses were performed
in a blinded fashion by a single investigator using ImageJ
(NIH, USA). All tests were conducted by the same investiga-
tor to avoid bias. Coefficients of variation for handgrip
strength and vastus lateralis cross-sectional area were
4.1% and 3.5%, respectively. Demographic, clinical, and bio-
chemical data of the patients were obtained through med-
ical records.
Outcome and stratification of patients
Our primary outcome was LOS, defined as time (days) from
hospital admission to medical discharge. To examine whether
muscle strength or mass were predictive of LOS, we ranked
patients according to handgrip strength and vastus lateralis
cross-sectional area into sex-specific tertiles. Then, we com-
pared the highest tertile (High) versus the combined mid
and lowest tertiles (High vs. Other), and the lowest tertile
(Low) versus the combined mid and highest tertiles (Low vs.
Other).
Sample size and statistical analyses
An a priori sample size estimate was made to achieve small
optimism in the predictor effect estimates as defined by a
global shrinkage factor of 0.9.19 The expected shrinkage is
conditioned on the sample size (n), the total number of pre-
dictors (p) and a generalization of the proportion of variance
explained for multivariable models with time-to-event out-
comes (R2CSapp).
19 For the present study, p was set to 6 and
R2CSapp to 0.5 based on findings from previous research
8,20,21
and therein, indicating a required sample size of n = 184.
Guided by this estimate, a total of 196 patients were evalu-
ated during their hospital stay.
The outcome (LOS) was analysed with multivariable Cox
proportional baseline hazard models with surviving patients
only and adjusted for sex (male or female), age group (18–
35, 36–55, or ≥56), obesity (BMI < 30 or BMI ≥ 30), oxygen
support at admission (0–4 L, 5–9 L,and ≥10 L), and Type 2 di-
abetes (yes or no). Both crude and adjusted hazard ratios
(HRs) were estimated for handgrip strength and vastus
lateralis cross-sectional area. Each predictor was assessed as
both a discrete and continuous predictor. Discrete models
were conducted by calculating sex-specific tertiles as origi-
nally planned and then focusing on either the largest tertile
(High vs. Other) or the smallest tertile (Low vs. Other). Con-
tinuous models were also included and conducted by stan-
dardizing predictor values relative to the sex-specific mean
and standard deviation. HRs were accompanied with
corresponding 95% confidence intervals (95% CI), with all
analyses performed in the statistical environment R (version




One hundred ninety-six patients were evaluated. Ten patients
did not test positive for SARS-CoV-2 during the hospitaliza-
tion period and were excluded from the analyses. Table 1
shows the demographic, biochemical, and clinical characteris-
tics of the patients. Overall, 86% (160 of 186) had a positive
PCR test for SARS-CoV-2 at the enrollment, and 42% had
computed tomography scan findings suggestive (i.e. pulmo-
nary commitment ≥50%) for COVID-19. All the remaining
Figure 1 Kaplan–Meier plot of time from hospital admission to hospital
discharge according to handgrip strength.
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patients (26 of 186) had the diagnosis confirmed by serology
assay (ELISA) to detect IgG against SARS-CoV-2 at some point
during the hospital stay. The sample comprised patients of
both sexes (50% male) with a mean (SD) age of 59 years
(±15) and a body mass index of 29.5 kg/m2 (±6.9). The prev-
alence of current smoking patients was 24.7%, and more
prevalent coexisting conditions were hypertension (67.7%),
obesity (40.9%), and type 2 diabetes (36.0%).
The signs and symptoms more commonly observed at ad-
mission were dyspnoea (81.2%), cough (64.4%), fever
(57.5%), myalgia (26.9%), fatigue (25.3%), headache (22.0%),
anosmia (19.9%), diarrhoea (17.7%), dysgeusia (17.2%), nau-
sea (11.3%), abdomen pain (10.2%), chest pain (10.2%),
vomiting (9.7%), runny nose (9.1%), earache (4.3%), and dizzi-
ness (1.1%).Mean (SD) LOSwas 8.6 days (7.7); 17.0% of the pa-
tients required intensive care; 3.8% used invasive mechanical
ventilation; and 6.6% died during the hospitalization period.
Primary outcome
The crude HR for time from hospital admission to discharge
was greatest for handgrip strength comparing the strongest
versus other patients (1.47 [95% CI: 1.07–2.03; P = 0.019]).
Evidence of an association between increased handgrip
strength and shorter hospital stay was also identified
when handgrip strength was standardized according
to the sex-specific mean and standard deviation
(1.23 [95% CI: 1.06–1.43; P = 0.007). The magnitude
of these associations remained consistent and
statistically significant after adjusting for other covariates
(Figure 1). Mean LOS was shorter for the strongest
patients (7.5 ± 6.1 days) versus others (9.2 ± 8.4 days)
(Table 2).
Similar results and evidence of associations were also pres-
ent for vastus lateralis cross-sectional area. The crude HR
identified shorter hospital stay for patients with greater
sex-specific standardized values (1.20 [95% CI: 1.03–1.39;
P = 0.016). Evidence was also obtained associating longer
hospital stays for patients with the lowest values for vastus
lateralis cross-sectional area (0.63 [95% CI: 0.46–0.88;
P = 0.006). The magnitude of these associations remained
consistent and statistically significant after adjusting for other
covariates (Figure 2). Mean LOS for the patients with the low-
est muscle cross-sectional area was longer (10.8 ± 8.8 days)
versus others (7.7 ± 7.2 days) (Table 2).
Table 2 Crude and adjusted hazard ratio (HR) for hospital length of stay in surviving patients
Crude HR (95% CI) P value Adjusted HR (95% CI) P value
Sex
Male 1 (ref) 1 (ref)
Female 0.82 (0.60–1.10) 0.186 0.81 (0.59–1.13) 0.216
Age, years
18–35 years 1 (ref) 1 (ref)
36–55 years 0.69 (0.37–1.29) 0.239 0.70 (0.36–1.37) 0.299
≥56 years 0.63 (0.35–1.15) 0.132 0.64 (0.34–1.20) 0.164
Oxygen support at admission
0–4 L 1 (ref) 1 (ref)
5–9 L 1.42 (0.92–2.19) 0.111 1.34 (0.85–2.11) 0.210
≥10 L 1.08 (0.63–1.84) 0.787 0.96 (0.54–1.72) 0.897
Obesity
BMI < 30 1 (ref) 1 (ref)
BMI ≥ 30 1.1 (0.80–1.47) 0.619 1.04 (0.66–1.30) 0.802
Type 2 diabetes
Yes 1 (ref) 1 (ref)
No 0.93 (0.67–1.28) 0.637 0.93 (0.66–1.30) 0.667
Handgrip strength: High vs. Other
Other 1 (ref) 1 (ref)
High 1.47 (1.07–2.03) 0.019* 1.48 (1.05–2.09) 0.024*
CSAVL: High vs. Other
Other 1 (ref) 1 (ref)
High 1.05 (0.76–1.45) 0.770 0.88 (0.59–1.32) 0.534
Handgrip strength: Low vs. Other
Other 1 (ref) 1 (ref)
Low 0.90 (0.65–1.24) 0.510 0.94 (0.66–1.33) 0.713
CSAVL: Low vs. Other
Other 1 (ref) 1 (ref)
Low 0.63 (0.46–0.88) 0.006** 0.59 (0.40–0.87) 0.007**
Handgrip strength: Standardized 1.23 (1.06–1.43) 0.007** 1.26 (1.07–1.48) 0.005**
CSAVL: Standardized 1.20 (1.03–1.39) 0.016* 1.24 (1.03–1.50) 0.023*
CSAVL, vastus lateralis cross-sectional area.
The Cox proportional hazards model was adjusted by sex (male or female), age (18–35, 36–55, or ≥56 years), oxygen support at admission
(0–4 L, 5–10 L, and ≥10 L), obesity (BMI < 30 and BMI > 30), and type 2 diabetes (yes or no).
*P < 0.05.
**P < 0.01.
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Discussion
In this prospective observational study, we found muscle
strength (as assessed by handgrip) and muscle mass (as
assessed by vastus lateralis cross-sectional area) are predic-
tive of LOS in hospitalized patients with moderate to severe
COVID-19. To the best of our knowledge, this is the first study
to demonstrate the prognostic value of these skeletal muscle
parameters in this disease.
A recent study demonstrated that the Clinical Frailty Score
(CFS) independently predicted time to medical discharge and
mortality in COVID-19 patients.20 Despite the value of these
findings, it is noteworthy that the CFS is a judgement-based
frailty tool that relies highly on experience and training for
proper categorization of the patients. Moreover, CFS is ulti-
mately an indirect measure of functional status and is mainly
used in geriatric patients. These are factors that might limit
the reliability of CFS in real-life clinical scenarios. Conversely,
handgrip strength is a simple, direct, easy handling, low-cost
measurement commonly utilized in the clinical setting as an
indicator of the general health status in individuals across a
wide age range. Indeed, handgrip strength assessed at hospi-
tal admission have been shown to be a predictive measure of
LOS and mortality in distinct populations.7–11 Our findings ex-
tend this knowledge to patients admitted into the hospital
with acute COVID-19 symptoms, by showing that stronger pa-
tients had lower LOS than their weaker counterparts.
Muscle mass is also considered as an indicator of general
health status.24,25 Previous studies have suggested that low
muscle mass (assessed by mid-arm circumference, calf cir-
cumference, and estimated by anthropometric equations)
may predict mortality among elderly.24,25 In the current
study, we directly assessed, in the point-of-care, vastus
lateralis cross-sectional area using ultrasonography among
patients with COVID-19. Our findings suggest that low muscle
mass could contribute to higher LOS among COVID-19 pa-
tients. During a critical illness, net breakdown of muscle pro-
tein is stimulated to provide abundant amino acids to meet
these increased demands of tissues such as immune cells
and liver.14 In this context, patients with limited muscle mass
reserves would presumably be more vulnerable to stress fac-
tors, such as severe burn injuries and cancer.26,27 The present
findings suggest that this could be the case of COVID-19.
Muscle mass plays a key role in recovery from critical ill-
ness, whereas muscle strength and function are key to the re-
covery process.12 If there is a preexisting deficiency of muscle
mass before the onset of an acute illness, one may speculate
that the expected loss of muscle mass and function associ-
ated with hospitalization may push the patient over a thresh-
old that makes recovery of normal function unlikely to ever
occur.12 The impact of this physiopathological mechanism
on long-term effects of COVID-19 (long COVID) remains to
be explored.
Limitations
First, the longitudinal design of this study does not allow
causative conclusions. Second, although this study was ade-
quately powered to detect changes in the selected outcomes,
this was still a small cohort composed by patients with het-
erogeneous clinical features, medication regimen and disease
manifestations, possibly subject to unmeasured confounders.
While the Cox proportional hazards models were controlled
for several potentially confound variables, direct sub-group
comparisons were not possible due to sample size con-
straints. Third, our results are confined to patients with mod-
erate to severe COVID-19 and should be read with care
regarding other clinical settings. Finally, the minimal clinically
important difference in LOS among patient with COVID-19 is
yet unknown, which limits the ability to make clinical infer-
ences about the present findings.
Figure 2 Kaplan–Meier plot of time from hospital admission to hospital
discharge according to vastus lateralis cross-sectional area.
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Conclusions
Muscle strength and mass assessed on hospital admission are
predictors of LOS in patients with COVID-19. While it is un-
known whether these muscular parameters add to the prog-
nostic value provided by the more established and accepted
predictors that already have been identified,28 the present
data suggest that muscle health may benefit patients with
moderate to severe COVID-19. The evidence provided by this
study paves the way for randomized controlled trials to test
the utility of preventive or in-hospital interventions in short-
ening LOS among these patients through improving muscle
mass and/or function.
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